Biousian Biosystems, Inc. (bbi)

Lexington, MA 02421

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $1.18MM
First Award Date 08/15/09
Most Recent Award Date 04/01/12

Key Personnel

Last Name Name Awards Contact
Kleven Mark S Kleven 2
Kitsos Christine M Kitsos 1

3 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 04/01/12 - 03/31/13

DESCRIPTION (provided by applicant): Traditionally, Mu opioid receptor (MOR) agonists have not been given as first line treatments for neuropathic pain due to their significant adverse side effects. Biousian Biosystems Inc, (BBI) is developing novel glycosylated peptide-based delta opioid receptor (DOR) targeted drugs for the treatment of chroni...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 04/01/11 - 03/31/12

DESCRIPTION (provided by applicant): Traditionally, Mu opioid receptor (MOR) agonists have not been given as first line treatments for neuropathic pain due to their significant adverse side effects. Biousian Biosystems Inc, (BBI) is developing novel glycosylated peptide-based delta opioid receptor (DOR) targeted drugs for the treatment of chroni...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/15/09 - 07/31/10

DESCRIPTION (provided by applicant): Biousian Biosystems Inc. (BBI) intends to develop novel, glycosylated, deltorphin-based peptides as orally available drugs for the treatment of chronic inflammatory pain. By targeting a 4-selective mechanism, it is anticipated that compounds with improved efficacy and fewer side effects, including less abuse ...